Motif Bio Submits NDA for Iclaprim

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the completion of its rolling submission of a New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news